Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

Name: Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
Published: 2017
License: Public Domain

M.D. Anderson Cancer Center · 2017

ClinicalTrials.gov · Datasets · License: Public Domain · 2017

Open Source ↗

pembrolizumab

melanoma and other malignant neoplasms of skin, metastatic melanoma, gsk2633771, pembrolizumab, keytruda, mk-3475, sch-900475, interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

Related documents